Navigation Links
EuroPCR in Medical News

Volcano Announces OCT Activities at EuroPCR 2009

Volcano's Axsun Laser - At the Heart of OCT SAN DIEGO and BARCELONA, Spain, May 19 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC ), a leader in the development, manufacturing and sales of products for the diagnosis of coronary and peripheral artery disease, today highlights it...

Abbott Announces EuroPCR 2009 Activities

- New data to be presented on Abbott's market-leading XIENCE V(R) stent - Educational information available on XIENCE PRIME(TM), Abbott's next-generation drug eluting stent in development BARCELONA, Spain, May 18 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) today announced the company...

Boston Scientific Announces Schedule for EuroPCR 2009

NATICK, Mass., May 15 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the schedule of the Company's events and news announcements at the annual EuroPCR Scientific Program, which runs from May 19 to 22 in Barcelona, Spain. "We are pleased to be announcing...

CorNova to Present at the Glimpse into the Future: Emerging Drug-Eluting Stents Symposium at EuroPCR 2009

S. Eric Ryan, M.D., Will Discuss the Valecor Platinum(TM) Coronary Stent System on the FiberHalo(TM) Balloon Angioplasty Catheter BURLINGTON, Mass., May 14 /PRNewswire/ -- CorNova Inc. today announced S. Eric Ryan, M.D., the company's chairman and chief executive officer, will present the Val...

LightLab Imaging Introduces World's Highest Resolution OCT System for Intracoronary Imaging at EuroPCR 2009

Launch of C7XR(TM) FD-OCT Imaging System and Companion C7 Dragonfly(TM) Imaging Catheter Strengthen LightLab's Market Leadership WESTFORD, Mass., May 14 /PRNewswire/ -- LightLab Imaging Inc., the pioneer and leader in the development of Optical Coherence Tomography (OCT) for vascular and othe...

PLC Medical Systems to Demonstrate RenalGuard(TM) at EuroPCR 2008

FRANKLIN, Mass., May 12 /PRNewswire-FirstCall/ -- PLC Systems Inc. (AMEX: PLC ), a company focused on innovative cardiac and vascular medical device-based technologies, announced today that it will demonstrate its RenalGuard System(TM) at EuroPCR, the annual meeting of the European Associatio...

Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study

...y Consistent with Superior Results from Randomized Clinical Trials BARCELONA, Spain, May 21 /PRNewswire-FirstCall/ -- New data presented today at europcr from an international, post-approval, single-arm study show that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System demonstr...

SYNTAX Substudy Shows Positive Outcomes for Left Main Patients Treated With TAXUS(R) Express2(R) Stent System

... narrowing of all three coronary arteries (three-vessel disease). The substudy data were presented by A. Pieter Kappetein, M.D., Ph.D., at the annual europcr Scientific Program in Barcelona. SYNTAX-LE MANS compares late angiographic and clinical outcomes in 263 patients with left main disease (149 trea...

XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention

... the publication after presenting it at the annual europcr meeting. "I am very pleased to congratulate Dr. ...ll that need." The paper and presentation at the europcr meeting discussed the previously released positive...s. EuroIntervention is the official publication of europcr and the European Association of Percutaneous Cardi...

TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients with Diabetes Compared to Non-Diabetics in ARRIVE Registry Program

...nd non-diabetic patients. Analysis of the data was presented by David A. Cox, M.D., F.A.C.C., and John M. Lasala, M.D., Ph.D., F.A.C.C., at the annual europcr Scientific Program in Barcelona. "The ARRIVE diabetic subset data demonstrated that the TAXUS Stent mitigated the adverse effect of diabetes as a ri...
EuroPCR in Medical Technology

Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents

Other Presentations Highlight Pre-clinical Work of Company's Future Pro-healing Technologies BARCELONA, Spain, May 20 /PRNewswire/ -- OrbusNeich announced today that two year follow up data from a single center, randomized clinical study in patients at high risk of restenosis were presented a...

PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009

Live Case Demonstrating RenalGuard To Be Presented FRANKLIN, Mass., May 15 /PRNewswire-FirstCall/ -- PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate its RenalGuard Sy...

Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents

Randomized TRIAS HR Pilot Study Compares Genous, Boston Scientific's Taxus(R) Other Presentations Focus on Real-World Use of Genous, Stent's Performance in Patients with AMI, Those Who Could Not Tolerate Dual-Antiplatelet Therapy ...

XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting

Company Will Host Webcast to Review Data Tuesday, May 13 at 1:00 p.m. EDT (7:00 p.m. CEST) BARCELONA, Spain and MENLO PARK, Calif., May 13 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT ) today announced positive six-month follow-up data from the CUSTOM III clin...

Data from Randomized Pilot Study, Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008

Other Data Presentations to Focus on Use of Pro-Healing Stent with AMI Patients and Those Who Cannot Tolerate Dual-Antiplatelet Therapy HONG KONG, May 8 /PRNewswire/ -- Twelve-month follow-up data from both a randomized pilot study and the real-world registry use of OrbusNeich's Genous Bio...

XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week

Webcast to Review CUSTOM III Six-Month Data to be held Tuesday, May 13th MENLO PARK, Calif., May 7 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT ) today announced that six-month follow-up data from the CUSTOM III trial will be presented at EuroPCR, taking place May 13 to 16 in Barcelona...

Boston Scientific Announces Schedule for EuroPcr 2007

Company to release broad range of clinical data on leading drug-eluting stent portfolio NATICK, Mass., May 15, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced the schedule of the Company's major events and press announcements at the annual Paris Course on Revasculariza...

XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting

Trial Included One of the Most Challenging Patient Populations Studied of Any Drug-Eluting Stent (DES) Clinical Trial BARCELONA and MENLO PARK, Calif., May 22, 2007 /PRNewswire-FirstCall/ -- XTENT, Inc. announces positive six-month follow-up data from the CUSTOM II clinical trial, which assessed t...

Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial Results at EuroPCR 2007

BARCELONA, Spain, May 22, 2007 /PRNewswire/ -- Principal investigators for the COSTAR II (CObalt Chromium STent with Antiproliferative for Restenosis) trial, the pivotal study for the CoStar(R) cobalt chromium paclitaxel-eluting coronary stent, presented today the clinical trial results of the stu...

Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR

BARCELONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Professor Ian Meredith, M.D., Monash Medical Centre, Melbourne, Australia, on Tuesday presented positive nine-month results from the Medtronic RESOLUTE clinical trial at the EuroPCR meeting in Barcelona, Spain, with data showing a low number of adve...
EuroPCR in Biological Technology

InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR '09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le

BARCELONA, Spain, May 20 /PRNewswire/ -- InspireMD, Ltd. announced today the completion of enrolment for the MAGICAL trial (MGuard(TM) in Acute Myocardial). The trial was designed to confirm the clinical feasibility, safety and performance of MGuard when used during Primary PCI in STEMI patien...

Prescient Medical, Inc. to Present Data on Identification and Treatment of Rupture-Prone Coronary Plaques at EuroPCR 2008

Company Pursues Strategy of Reducing Heart Attack Deaths by Shielding High-Risk Plaques in Coronary Arteries DOYLESTOWN, Pa., May 8 /PRNewswire/ --- Prescient Medical, Inc., a privately held medical device company dedicated to reducing deaths from heart attacks, will present n...

SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System

...t narrowing of all three coronary arteries (three-vessel disease). The substudy data were presented by A. Pieter Kappetein, M.D., Ph.D., at the annual europcr Scientific Program in Barcelona. SYNTAX-LE MANS compares late angiographic and clinical outcomes in 263 patients with left main disease (149 treated...

First Use in Coronary Patients of a Combined Near-Infrared Spectroscopy and Ultrasound Imaging Catheter

...s with coronary artery disease." Live patient case to be broadcast at europcr Conference this week On Wednesday, May 20, Dr. van der Ent will be pe...orming a live case with the combined catheter from the Thoraxcenter for the europcr Conference taking place this week in Barcelona, Spain from May 19 - 22, 200...

Boston Scientific Welcomes Launch of Syntax Score Website

...YNTAX Score(TM), a novel angiographic tool used to measure the complexity of coronary artery disease. The Company made the announcement at the annual europcr Scientific Program in Barcelona. The SYNTAX Score was developed in connection with the SYNTAX trial, the first randomized, controlled clinical tr...

Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability

...s. Over and Under(R) PCS was presented by Dr. Haim Danenberg, Head of Interventional Cardiology Unit and the company's medical director, at the annual europcr meeting. Study was performed in phantom and porcine coronaries. Over and Under(R) PCS appeared to be significantly superior in deliverability in both ...

Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System

... 2006. This announcement comes just prior to Volcano's participation in the europcr 2008 Congress, to be held in Barcelona, Spain, from May 12-15th. During the...xible than ever before. Presence at EuroPCR08 Volcano's presence at the europcr 2008 Congress in Barcelona will include live case transmissions with IVUS, ...

Biopure Announces 2008 First Quarter Financial Results

... Association of Interventional Cardiology. EIJ is a peer-reviewed journal of interventional cardiovascular medicine and is the official publication of europcr and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). The accepted manuscript reports on the Company's first pilot isch...
Other Tags
(Date:8/20/2014)... Ticket Down is a reliable source for authentic ... just a week, the U.S. Open Tennis Championship will kick off ... originally founded in 1881 and features grass courts since 1978. The ... from the event because of a wrist injury. Serena Williams was ... New York City with hopes of winning her sixth U.S. Open ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. ... dramatically during the past two decades, plummeting 57 percent and ... An estimated 4 million fewer births occurred among teenagers ... the U.S. Centers for Disease Control and Prevention. That ... report," said Bill Albert, chief program officer of The National ...
(Date:8/20/2014)... patient and tumor characteristics for melanomas with higher ... in an effort to increase earlier detection of ... , Author: Sarah Shen, M.B.B.S., B.Med.Sci., of Alfred ... The tumor characteristic known as mitotic rate ... prognosis and survival in melanoma patients. However, the ...
(Date:8/20/2014)... discovered that the immune system is defective in people suffering ... sufferers have ongoing issues with pain. , The research ... also help to explain why some painkillers may not offer ... up to 10% of the community. There are different ... pain, which often has the greatest impact on sufferers, quality ...
(Date:8/20/2014)... now, Free content, The time to deploy Ebola ... published early online today in Annals of ... of Public Health write that the relentless epidemiologic trajectory ... a public health crisis that shows no signs of ... developed in the last decade, yet the sporadic nature ...
Breaking Medicine News(10 mins):Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 2Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 3Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 4Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 5Health News:Teen Birth Rate Has Dropped Dramatically in Last Two Decades: CDC 2Health News:Teen Birth Rate Has Dropped Dramatically in Last Two Decades: CDC 3Health News:Patient, tumor characteristics for high-mitotic rate melanoma 2Health News:Pain treatments less effective for those with irritable bowel 2Health News:News from Annals of Internal Medicine 2
(Date:8/20/2014)... at Huntsman Cancer Institute (HCI) at the University of ... gene that encodes BCR-ABL, the unregulated enzyme driving the ... American Cancer Society, nearly 6,000 new cases of CML ... use, called tyrosine kinase inhibitors (TKIs), target BCR-ABL and ... cure CML but control it in a way that ...
(Date:8/20/2014)... University, the Wellcome Trust Sanger Institute and the Swiss ... Mycobacterium pinnipedii from skeletons found in Peru which ... a relative of the TB bacterium that affects seals ... researchers assume that seals carried the pathogens from Africa ... was unexpected" comments Sebastien Gagneux, from the Swiss Tropical ...
(Date:8/20/2014)... 19, 2014 -- Bay Area Lyme Foundation, which aims ... to cure, applauds new research published in an upcoming ... and Tick-borne Diseases . The findings show that ... active throughout the year, making the threat of Lyme ... California Department of Public Health (CDPH) Vector-borne Disease Section ...
Breaking Biology News(10 mins):Blueprint for next generation of chronic myeloid leukemia treatment 2Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
Other Contents